lobbying_activities: 1114518

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1114518	c0acace8-c62f-489c-b8d4-47049f65432c	Q2	GENENTECH, INC	15920	GENENTECH INC	2011	second_quarter	PHA	Public Law 111-148, the Patient Protection and Affordable Care Act - Implementation issues related to FDA approval of follow-on biologics and length of data exclusivity period, 340B drug pricing program, structure of the Medicar prescription drug benefit. Public Law 111-152, the Health Care and Education Reconciliation Act of 2010 - Implementation issues related to Medicare and Medicaid reimbursement, fees assessed on the pharmaceutical industry, design and structure of the Medicare prescription. drug benefit. General issue and congressional oversight related to FDA approval and CMS coverage decisions regarding. Avastin and Lucentis.	HOUSE OF REPRESENTATIVES,SENATE		1140295	0	0	2011-07-15T15:29:33.307000-04:00